Dicerna Pharmaceuticals (DRNA) gained 207% and Ultragenyx (RARE) followed with a 101% first-day jump the next day as the biotech boom reached a new gear last week. Dicerna’s first-day return was the best since Baidu’s IPO in 2005 (+354%), and...read more
Trevena, a clinical-stage biotech developing treatments for pain and acute heart failure, raised $65 million by offering 9.3 million shares at $7, as expected. Prior to postponing its IPO in November 2013, the company had been looking to raise $75 million at a...read more
Trevena, a clinical-stage biotech developing treatments for pain and acute heart failure, lowered the proposed deal size for its upcoming IPO on Wednesday. The King of Prussia, PA-based company now plans to raise $60 million by offering 8.5 million shares at $7...read more
Trevena, a clinical-stage biotech developing treatments for pain and acute heart failure, postponed its IPO on Wednesday citing poor market conditions. The King of Prussia, PA-based company was founded in 2007. Barclays and Jefferies & Co. were set to be the...read more
US IPO Recap: Ultragenyx doubles and Dicerna triples in home-run week for biotech IPOs
Dicerna Pharmaceuticals (DRNA) gained 207% and Ultragenyx (RARE) followed with a 101% first-day jump the next day as the biotech boom reached a new gear last week. Dicerna’s first-day return was the best since Baidu’s IPO in 2005 (+354%), and...read more
UPDATED: Trevena prices upsized IPO at $7, as expected
Trevena, a clinical-stage biotech developing treatments for pain and acute heart failure, raised $65 million by offering 9.3 million shares at $7, as expected. Prior to postponing its IPO in November 2013, the company had been looking to raise $75 million at a...read more
Trevena decreases IPO price to $7 and increases shares offered, deal size is now $60 million
Trevena, a clinical-stage biotech developing treatments for pain and acute heart failure, lowered the proposed deal size for its upcoming IPO on Wednesday. The King of Prussia, PA-based company now plans to raise $60 million by offering 8.5 million shares at $7...read more
Trevena postpones IPO
Trevena, a clinical-stage biotech developing treatments for pain and acute heart failure, postponed its IPO on Wednesday citing poor market conditions. The King of Prussia, PA-based company was founded in 2007. Barclays and Jefferies & Co. were set to be the...read more